

1 David B. Robbins (*pro hac vice*)
Washington Bar No. 13628
2 Renee M. Howard (*pro hac vice*)
Washington Bar No. 38644
3 Bennett Bigelow & Leedom, P.S.
1700 Seventh Avenue, Suite 1900
4 Seattle, WA 98101
Telephone: 206-622-5511
5 Facsimile: 206-622-8986
Email: [drobbins@bblaw.com](mailto:d Robbins@bblaw.com)
6 Email: [rhoward@bblaw.com](mailto:r Howard@bblaw.com)

7 Counsel for Defendants
Providence Health & Services & Osamu Matsutani, M.D.
8

9
10 IN THE UNITED STATES DISTRICT COURT
DISTRICT OF ALASKA

11 UNITED STATES OF AMERICA, *Ex rel.* Law
Project for Psychiatric Rights, and Alaskan non-
12 profit Corporation,

Case No. 3:09-cv-0080-TMB

13 Plaintiff,

14 vs.

15 OSAMU H. MATSUTANI, MD, et al.,

16 Defendant.

17 UNITED STATES OF AMERICA, *ex rel.* Daniel I
Griffin,

Case No. 3:09-cv-246-TMB

18 Plaintiff,

19 vs.

(CONSOLIDATED)

20 RONALD A. MARTINO, MD, FAMILY
21 CENTERED SERVICES OF ALASKA, INC., an
Alaska corporation, and SAFEWAY, INC., a
22 Delaware corporation, et al.,

23 Defendants.

24 **REPLY OF CERTAIN DEFENDANTS IN SUPPORT OF MOTION**
25 **FOR ATTORNEY FEES AND EXPENSES UNDER 31 U.S.C. § 3730(d)(4)**

I. INTRODUCTION

The undersigned Defendant physicians, hospitals, and nonprofit community mental healthcare providers hereby reply to the Opposition filed by Plaintiff Law Project for Psychiatric Rights (“PsychRights”) to Defendants’ Motion for Attorney Fees and Expenses under the False Claims Act (“FCA”), 31 U.S.C. § 3730(d)(4).¹ Despite PsychRights’ protests to the contrary, this is the unusual case in which the high standard for imposition of attorney fees is met by PsychRights’ knowing pursuit of publicly disclosed allegations that added absolutely no inside information of fraud.

Specifically, this case is plainly frivolous, vexatious or interposed for purposes of harassment when viewed in light of the fact that (i) PsychRights was aware that its essential allegations of fraud were in the public domain and available to the government, (ii) PsychRights never professed to be an original source, (iii) the case replicated PsychRights’ own failed prior state court litigation, and (iv) there was no reason for Defendants to resort to falsity or subterfuge in order to obtain Medicaid payment for drugs from the Alaska Medicaid program as that program knowingly paid for the drugs in question.

II. ARGUMENT

A. **PsychRights Had No Reasonable Basis to Believe Its Case Was Not Jurisdictionally Barred.**

Although it argues its case was not frivolous, PsychRights cannot dispute that it unsuccessfully litigated essentially identical claims against the State of Alaska previously—*i.e.*, that the Alaska Medicaid program knowingly paid for psychiatric drugs prescribed off-label to children and youth for indications not listed in certain drug data compendia. That case, *PsychRights v. Alaska*, embodies two fundamental problems with this case that render it frivolous: (i) PsychRights’ improper use of the FCA to advance a social agenda; and (ii) its

¹ Dkt. 196.

1 knowledge that the essential allegations of fraud were well-known or discoverable by the
2 federal government long before PsychRights filed this case.

3 *First*, PsychRights admitted to the government when it filed its case that its FCA
4 claims were an additional avenue to pursue the relief it sought in *PsychRights v. Alaska, i.e.*,
5 to enjoin State reimbursement of off-label psychiatric drugs prescribed to pediatric patients.²
6 Subsequent public statements that it was not bringing this case “for the money” were not
7 simply a profession of altruism, as PsychRights suggests.³ Instead, the statements confirm
8 that this lawsuit was not about restoring money to government coffers. Indeed, PsychRights’
9 actions throughout this litigation have run contrary to the government’s interests and the
10 financial interest of a true whistleblower. For example, it filed a frivolous motion to show
11 cause against the United States and opposed routine seal extensions while the government
12 investigated PsychRights claims at the outset of litigation. It even took the extraordinary step,
13 unheard of in FCA cases, of filing a motion to preliminarily enjoin Medicaid reimbursement
14 of off-label psychotropic medications for children and youth, an action that was antithetical to
15 the financial interest of an FCA relator, redundant to what it unsuccessfully attempted to
16 accomplish in *PsychRights v. Alaska*, and plainly vexatious because it lacked any legal
17 justification.

18 *Second*, PsychRights’ state case is only one of several examples that its allegations of
19 fraud were in the public domain when it brought this case, and PsychRights knew it. The fact
20 that the public disclosures were well-known to PsychRights, and in the case of *PsychRights v.*
21 *Alaska*, were *caused* by PsychRights, further demonstrates the frivolous and vexatious nature
22 of its supposed “whistleblower” claims here, as well as its defense to the pending fee motion.

23
24 ² See Dkt. 158-1 at 3 (describing the state court case and noting that “the False Claims Act
25 might be an additional avenue to pursue to end the pervasive practice of prescribing harmful,
26 ineffective, psychiatric drugs to children and youth”).

³ Dkt. 196 at 6.

1 PsychRights' concession that it is not an original source of its allegations of fraud is grounds
2 enough for concluding its FCA claims were frivolous. Without inside information of its fraud
3 claims, PsychRights is not the sort of relator that Congress intended to encourage by the *qui*
4 *tam* provisions of the FCA, and has no basis to proceed under that law.⁴

5 Unsurprisingly, PsychRights argues that despite its lack of original source status, it
6 had a reasonable basis to believe the public disclosure bar would not apply based on its
7 crabbed reading of Ninth Circuit public disclosure bar cases involving widespread fraud
8 throughout an industry.⁵ As this Court correctly held, PsychRights' reading of these cases is
9 wrong.⁶ The public disclosure bar does not require that allegations of industry-wide fraud
10 identify the individual defendants unless their identity would be a mystery otherwise.⁷ Here,
11 PsychRights simply took aim at prominent Alaska providers of pediatric mental health
12 services and the pharmacies that serve them. Were the government interested in pursuing the
13 theory of fraud set out in the various public disclosures (including nearly identical allegations
14 in *PsychRights v. Alaska*), it could have done the same thing. Moreover, PsychRights brought
15 no new information to the government by naming the numerous defendants in this case, as
16 this information could have been provided by anyone with a copy of the yellow pages or
17 internet access.⁸ In short, PsychRights simply did what the government would have done

19 ⁴ See, e.g., *United States ex rel. Ebeid v. Lungwitz*, 616 F.3d 993, 999 (9th Cir. 2010) (“[T]he
20 FCA is geared primarily to encourage insiders to disclose information necessary to prevent
fraud on the government.”).

21 ⁵ See *United States ex rel. Harshman v. Alcan Elec. & Eng'g, Inc.*, 197 F.3d 1014, 1018-20
22 (9th Cir. 1999); *United States ex rel. Foundation Aiding the Elderly v. Horizon W. Inc.*, 265
23 F.3d 1011, 1014-15 (9th Cir. 2001); *United States ex rel. Alfatooni v. Kitsap Physicians*
Servs., 163 F.3d 516, 523 (9th Cir. 1999).

24 ⁶ Dkt. 163 at 16-18.

25 ⁷ See Dkt. 163 at 16 (quoting *Harshman*, 197 F.3d at 1018-19).

26 ⁸ PsychRights' utter lack of inside information is further betrayed by the fact that its
Complaint did not identify any facts relative to many of the Defendant, but offered only

1 with the information had it any interest in this matter—investigate and prosecute prominent
2 providers of the services, without knowing anything more about what they may have done.

3 Finally, the federal government-initiated proceedings against drug manufacturers for
4 off-label drug promotion cited by PsychRights do not demonstrate its case was not frivolous,
5 as it contends.⁹ To the contrary, these cases, which were uniformly brought against drug
6 companies, confirm the frivolity of a case that seeks to impose liability on downstream health
7 care providers and pharmacies for the alleged illegal and nefarious acts of the drug
8 companies. More importantly, these prosecutions demonstrate that the federal government
9 was aware of any impact that off-label marketing might have on claims submitted by
10 providers to payors like Medicaid. The government could have chosen to prosecute health
11 care providers for the same conduct alleged by PsychRights if it thought a case could be
12 made, but for obvious reasons has elected not to do so.¹⁰

13 **B. The Case Was Vexatious Because It Was Brought to Advance a Social**
14 **Agenda, Not to Restore Funds to the Government Under the FCA.**

15 PsychRights also argues that it did not pursue its case to be vexatious or for purposes
16 of harassment. This Court need not determine that the action was clearly vexatious or brought

17 formulaic recitations of its FCA cause of action in derogation of its responsibilities under
18 FRCP 9(b).

19 ⁹ Dkt. 196 at 4.

20 ¹⁰ While the government's litigation theories and strategy are unknown (and not relevant to
21 this fee motion), presumably it has not taken up a theory like the one PsychRights advances
22 because, unlike drug companies, prescribers are not subject to FDA labeling laws and, even if
23 they were the recipients of improper manufacturer marketing, under the laws of virtually all
24 states they were legally entitled to prescribe and dispense FDA-approved drugs for medically
25 appropriate care, irrespective of the FDA-approved labeled indications. Certainly the
26 government had all the information it needed to make this call—including information and
legal theories developed in off-label marketing cases brought against drug companies, and the
suggestion (via the Utah Attorney General) that state Medicaid programs that cover off-label
indications may be acting in violation of federal Medicaid law. It also had notice that the
federal Centers for Medicare and Medicaid Services was fully aware that state Medicaid
programs were covering the off-label use of drugs and approved of it.

1 to harass, however, if it concludes that the action was frivolous.¹¹ In any event, PsychRights’
2 subjective intent in filing its lawsuit is only relevant to whether the action was brought for
3 purposes of harassing the defendants.¹² The vexatious nature of the litigation is an objective
4 determination.¹³

5 PsychRights’ only rejoinder to Defendants’ characterization of its case as vexatious or
6 brought for an improper purpose is that its press releases and Disclosure Statement announce
7 that it is not motivated by financial gain.¹⁴ These representations, though, are entirely
8 consistent with vexatious or harassing litigation. They demonstrate the PsychRights was
9 using the FCA to advance a social agenda that was unrelated to any inside information of
10 fraud on the federal government. Further, PsychRights does not even address its other
11 vexatious actions taken that are manifestly inconsistent with *qui tam* litigation, such as
12 seeking a preliminary injunction to prevent further claims from being submitted, aggressively
13 contesting the federal government’s right to fully investigate its claims and, most importantly,
14 filing the case with the knowledge that it has no independent information that adds to publicly
15 available data. Nor does it refute the frivolous and vexatious nature of accusing providers of
16 fraud who, given the Alaska Medicaid program’s policy-based coverage of the drugs, had no
17 reason to submit false or fraudulent claims in order to obtain payment.

18 ¹¹ 31 U.S.C. § 3730(d)(4) (attorney fees may be awarded to defendants if the action is “clearly
19 frivolous,” “clearly vexatious,” or “brought primarily for purposes of harassment”).

20 ¹² *United States ex rel. Atkinson v. Pennsylvania Shipbuilding Co.*, 528 F. Supp. 2d 533, 544
21 (E.D. Pa. 2007) (“The existence of relator’s subjective intent distinguishes between vexatious
and harassing litigation.”).

22 ¹³ *See United States ex rel. Grynberg v. Praxair, Inc.*, 389 F.3d 1038, 1058 (10th Cir. 2004)
23 (“[T]he term ‘vexatious’ in no way implies that the plaintiff’s subjective bad faith is a
24 necessary prerequisite to a fee award against him . . . [A] district court may in its discretion
25 award attorney’s fees to a prevailing defendant . . . upon a finding that the plaintiff’s action
was frivolous, unreasonable, or without foundation, even though not brought in subjective bad
26 faith.”) (quoting *Christiansburg Garment Co. v. EEOC*, 434 U.S. 412, 421 (1978)).

¹⁴ Dkt. 196 at 6–7.

1 JERMAIN, DUNNAGAN & OWENS, P.C.
2 Attorneys for Anchorage Community
Mental Health Services, Inc.

3 By: /s/Howard S. Trickey (consented)

4 Howard S. Trickey
5 Alaska Bar No. 7610138
6 Cheryl Mandala
7 Alaska Bar No. 0605019
8 3000 A Street, Suite 300
9 Anchorage, AK 99503
10 Telephone: (907) 563-8844
11 Facsimile: (907) 563-7322
12 htrickey@jdolaw.com
13 cmandala@jdolaw.com

14 CLAPP, PETERSON, VAN FLEIN
15 TIEMESSEN & THORSNESS, LLC
16 Attorneys for Defendants Ronald A. Martino,
17 MD, Irvin Rothrock, MD, and Fairbanks
18 Psychiatric and Neurological Clinic

19 By: /s/John J. Tiemessen (consented)

20 John J. Tiemessen
21 Alaska Bar No. 9111105
22 411 Fourth Avenue, Suite 300
23 Fairbanks, Alaska 99701
24 Telephone: (907) 479-7776
25 Fax: (907) 479-7966
26 Email: jjt@cplawak.com

CLAPP, PETERSON, VAN FLEIN
TIEMESSEN & THORSNESS, LLC
Attorneys for Defendants Elizabeth Baisi, MD,
Ruth Dukoff, MD, Lina Judith Bautista, MD, Jan
Kiele, MD, and Frontline Hospitals, a Limited
Liability Company

By: /s/Linda J. Johnson (consented)

Linda J. Johnson
Alaska Bar No. 8911070
711 H Street, Suite 620
Anchorage, Alaska 99501
Telephone: (907) 272-9272
Fax: (907) 272-9586
Email: ljj@cplawak.com

1 SEDOR, WENDLANDT, EVANS &
2 FILIPPI, LLC
3 Attorneys for Defendants Kerry Ozer, MD and
4 Claudia Phillips, MD

5 By: /s/Allen Frank Clendaniel (consented)
6 Allen Frank Clendaniel
7 Alaska Bar No. 0411084
8 500 L Street, Suite 500
9 Anchorage, Alaska 99501
10 Telephone: (907) 677-3600
11 Fax: (907) 677-3605
12 Email: clendaniel@alaskalaw.pro

13 DORSEY & WHITNEY, LLP
14 Attorneys for Defendant Southcentral
15 Foundation

16 By: /s/Robert C. Bundy (consented)
17 Robert C. Bundy
18 Alaska Bar No. 7206021
19 1031 W. 4th Avenue, Suite 600
20 Anchorage, Alaska 99501
21 Telephone: (907) 257-7853
22 Fax: (907) 276-4152
23 Email: bundy.robert@dorsey.com

24 BROWN, WALLER & GIBBS, PC
25 Attorneys for Defendants Sheila Clark, MD and
26 Lucy Curtiss, M.D

By: /s/Keith Brown (consented)
Keith Brown
Alaska Bar No. 6903003
821 N Street, Suite 202
Anchorage, Alaska 99501
Telephone: (907) 276-2050
Fax: (907) 276-2051
Email: brownwag@alaska.net

1 SONOSKY, CHAMBERS, SACHSE,
2 MILLER & MUNSON, LLP
3 Attorneys for Defendants Heidi F.
4 Lopez-Coonjohn, MD, Robert D. Schults, MD,
5 Mark H. Stauffer, MD, and City and Borough of
6 Juneau, Alaska (Bartlett Regional Hospital)

7 By: /s/Kay Gouwens (consented)
8 Kay Gouwens
9 Alaska Bar No. 8106023
10 900 West 5th Avenue, Suite 700
11 Anchorage, Alaska 99501
12 Telephone: (907)258-6377
13 Fax: (907)272-8332
14 Email: kay@sonosky.com

15 Richard D. Monkman
16 Alaska Bar No. 8011101
17 302 Gold Street, Suite 201
18 Juneau, Alaska 99801
19 Telephone: (907) 586-5880
20 Fax: (907) 586-5883
21 Email: dick@sonoskyjuneau.com

22 LANE POWELL, LLC
23 Attorneys for Defendant Alternative Community
24 Mental Health d/b/a Denali Family Services

25 By: /s/Matthew W. Claman (consented)
26 Matthew W. Claman
Alaska Bar No. 8809164
301 W. Northern Lights Blvd., Suite 301
Anchorage, Alaska 99503-2648
Telephone: (907) 277-3311
Fax: (907) 276-2631
Email: clamanm@lanepowell.com

DELANEY WILES, INC.
Attorneys for Defendant
Peninsula Community Health
Services of Alaska, Inc.

By: /s/Howard A. Lazar (consented)
Howard A. Lazar
Alaska Bar No. 8604013
1007 West Third Avenue, Suite 400
Anchorage, Alaska 99501
Telephone: 907-279-3581
Fax: 907-277-1331
Email: hal@delaneywiles.com

Certificate of Service

I certify that on this 3rd day of November 2010, I caused a true and correct copy of the foregoing document to be served on all parties of record by electronic means through the ECF system as indicated on the Notice of Electronic Filing, or if not by ECF, by first class regular mail as follows:

Richard Pomeroy
Assistant U.S. Attorney
United States Attorney's Office
222 West 7th Avenue, #9
Anchorage, AK 99513-5071

Evan C. Zoldan
U.S. Department of Justice
Civil Division
Commercial Litigation Branch
Ben Franklin Station
Washington, D.C. 20044

/s/ David B. Robbins

{0310.00019/M0240576.DOCX; 4}